BR0214437A - Composto, composição farmacêutica, métodos de modular um receptor ativado por proliferador de peroxissoma, de tratar e de prevenir a diabete melito, e de tratar a sìndrome x, e doenças cardiovasculares em um mamìfero, e, uso de um composto - Google Patents
Composto, composição farmacêutica, métodos de modular um receptor ativado por proliferador de peroxissoma, de tratar e de prevenir a diabete melito, e de tratar a sìndrome x, e doenças cardiovasculares em um mamìfero, e, uso de um compostoInfo
- Publication number
- BR0214437A BR0214437A BR0214437-9A BR0214437A BR0214437A BR 0214437 A BR0214437 A BR 0214437A BR 0214437 A BR0214437 A BR 0214437A BR 0214437 A BR0214437 A BR 0214437A
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- compound
- group
- modulating
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODOS DE MODULAR UM RECEPTOR ATIVADO POR PROLIFERADOR DE PEROXISSOMA, DE TRATAR E DE PREVENIR A DIABETE MELITO, E DE TRATAR A SìNDROME X, E DOENçAS CARDIOVASCULARES EM UM MAMìFERO, E, USO DE UM COMPOSTO". A presente invenção esta direcionada aos compostos representados pela seguinte Fórmula Estrutural (I), (a) R^ 1^ é selecionado do grupo que consiste de hidrogênio, grupo substituído ou não substituído selecionado de alquila C~ 1~-C~ 8~, arilalquila C~ 0-4~, heteroarilalquila C~ 0-4~, cicloalquilarila C~ 3~-C~ 6~ alquila C~ 0-2~, e CH2-C(O)-R^ 17^-R^ 18^, em que R^ 17^ é O ou NH e R^ 18^ é benzila opcionalmente substituído; (b) R^ 2^ é selecionado do grupo que consiste de alquila C~ 1~-C~ 6~, alquenila C~ 1~-C~ 6~, arilalquila C~ 0-4~, heteroarilalquila C~ 0-4~, alquila C~ 1~-C~ 4~ sulfonamida, alquila C~ 1~-C~ 4~ amida, OR^ 10^ e cicloalquila C~ 3~-C~ 6~; (c) W é O ou S; (d) X é um ligador de alquileno C~ 1~-C~ 5~ opcionalmente substituído em que um átomo de carbono do ligador pode ser opcionalmente substituído com O, NH, S e opcionalmente dois carbonos juntos podem formar uma ligação dupla. (e) Y é selecionado do grupo consiste de C, O, S, NH e uma ligação simples; e (f) E é selecionado do grupo que consiste de C(R^ 3^) (R^ 4^)A, A. e um grupo substituído ou não substituído selecionado do grupo que consiste de (CH~ 2~)~ n~COOR^ 19^.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33445301P | 2001-11-30 | 2001-11-30 | |
PCT/US2002/036128 WO2003048130A2 (en) | 2001-11-30 | 2002-11-26 | Peroxisome proliferator activated receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0214437A true BR0214437A (pt) | 2004-10-13 |
Family
ID=23307275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0214437-9A BR0214437A (pt) | 2001-11-30 | 2002-11-26 | Composto, composição farmacêutica, métodos de modular um receptor ativado por proliferador de peroxissoma, de tratar e de prevenir a diabete melito, e de tratar a sìndrome x, e doenças cardiovasculares em um mamìfero, e, uso de um composto |
Country Status (19)
Country | Link |
---|---|
US (1) | US7544812B2 (pt) |
EP (1) | EP1453811A2 (pt) |
JP (1) | JP2005517643A (pt) |
KR (1) | KR20050044606A (pt) |
CN (1) | CN1582279A (pt) |
AU (1) | AU2002356927A1 (pt) |
BR (1) | BR0214437A (pt) |
CA (1) | CA2468846A1 (pt) |
CO (1) | CO5640129A2 (pt) |
EA (1) | EA007163B1 (pt) |
HR (1) | HRP20040469A2 (pt) |
HU (1) | HUP0402486A3 (pt) |
IL (1) | IL161578A0 (pt) |
MX (1) | MXPA04005123A (pt) |
NO (1) | NO20042737L (pt) |
NZ (1) | NZ532909A (pt) |
PL (1) | PL370515A1 (pt) |
WO (1) | WO2003048130A2 (pt) |
ZA (1) | ZA200404173B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003241579B9 (en) | 2002-06-19 | 2009-07-30 | Eli Lilly And Company | Amide linker peroxisome proliferator activated receptor modulators |
US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
DE10351859A1 (de) * | 2003-11-06 | 2005-06-09 | Beiersdorf Ag | Emulsionen mit zwei Verdickungsmitteln |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
KR101202066B1 (ko) * | 2004-09-28 | 2012-11-15 | 알러간, 인코포레이티드 | 특이적인 또는 선택적인 알파2 아드레날린성아고니스트로서 작용하는 비치환된 및 치환된4-벤질-1,3-디히드로-이미다졸-2-티온 및 이를 사용하는방법 |
KR20090021223A (ko) | 2006-06-20 | 2009-02-27 | 와이어쓰 | 이미다졸리디논 kv1.5 칼륨 채널 억제제 |
FR2903984B1 (fr) * | 2006-07-24 | 2008-10-03 | Genfit Sa | Derives d'imidazolones substitues, preparation et utilisations |
WO2008094860A2 (en) | 2007-01-30 | 2008-08-07 | Allergan, Inc. | Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists |
ES2393885T7 (es) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
CN101875636B (zh) * | 2010-05-18 | 2012-01-04 | 浙江大学 | 咪唑啉-2,4-二酮类衍生物及制备方法和用途 |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
CN114835655A (zh) * | 2022-04-14 | 2022-08-02 | 河南师范大学 | 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3452041A (en) | 1965-05-19 | 1969-06-24 | American Home Prod | Hydantoin compounds and methods of preparation |
NL7706064A (nl) | 1976-06-03 | 1977-12-06 | Wellcome Found | Werkwijze ter bereiding van heterocyclische verbindingen alsmede van farmaceutische pre- paraten die deze verbindingen als actieve component omvatten. |
GB1601310A (en) | 1978-05-23 | 1981-10-28 | Lilly Industries Ltd | Aryl hydantoins |
JPS59159163A (ja) * | 1983-03-01 | 1984-09-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−感光材料 |
GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
DK0966447T3 (da) | 1997-03-03 | 2003-06-23 | Boehringer Ingelheim Pharma | Anvendelige små molekyler til behandling af betændelsessygdomme |
DK1206457T3 (da) * | 1999-08-27 | 2004-02-16 | Lilly Co Eli | Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER |
-
2002
- 2002-11-26 CA CA002468846A patent/CA2468846A1/en not_active Abandoned
- 2002-11-26 CN CNA028238001A patent/CN1582279A/zh active Pending
- 2002-11-26 HU HU0402486A patent/HUP0402486A3/hu unknown
- 2002-11-26 MX MXPA04005123A patent/MXPA04005123A/es unknown
- 2002-11-26 IL IL16157802A patent/IL161578A0/xx unknown
- 2002-11-26 US US10/496,770 patent/US7544812B2/en not_active Expired - Fee Related
- 2002-11-26 EA EA200400748A patent/EA007163B1/ru not_active IP Right Cessation
- 2002-11-26 PL PL02370515A patent/PL370515A1/xx not_active Application Discontinuation
- 2002-11-26 JP JP2003549322A patent/JP2005517643A/ja active Pending
- 2002-11-26 EP EP02804416A patent/EP1453811A2/en not_active Withdrawn
- 2002-11-26 BR BR0214437-9A patent/BR0214437A/pt not_active IP Right Cessation
- 2002-11-26 AU AU2002356927A patent/AU2002356927A1/en not_active Abandoned
- 2002-11-26 NZ NZ532909A patent/NZ532909A/en unknown
- 2002-11-26 WO PCT/US2002/036128 patent/WO2003048130A2/en active Application Filing
- 2002-11-26 KR KR1020047008021A patent/KR20050044606A/ko not_active Application Discontinuation
-
2004
- 2004-05-27 ZA ZA200404173A patent/ZA200404173B/en unknown
- 2004-05-27 HR HR20040469A patent/HRP20040469A2/hr not_active Application Discontinuation
- 2004-05-27 CO CO04049275A patent/CO5640129A2/es not_active Application Discontinuation
- 2004-06-29 NO NO20042737A patent/NO20042737L/no unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0402486A3 (en) | 2007-05-02 |
HRP20040469A2 (en) | 2004-10-31 |
CO5640129A2 (es) | 2006-05-31 |
JP2005517643A (ja) | 2005-06-16 |
CN1582279A (zh) | 2005-02-16 |
PL370515A1 (en) | 2005-05-30 |
NZ532909A (en) | 2006-08-31 |
US20050020652A1 (en) | 2005-01-27 |
MXPA04005123A (es) | 2005-02-17 |
NO20042737L (no) | 2004-08-17 |
CA2468846A1 (en) | 2003-06-12 |
EP1453811A2 (en) | 2004-09-08 |
WO2003048130A3 (en) | 2003-11-20 |
EA007163B1 (ru) | 2006-08-25 |
US7544812B2 (en) | 2009-06-09 |
WO2003048130A2 (en) | 2003-06-12 |
EA200400748A1 (ru) | 2004-12-30 |
IL161578A0 (en) | 2004-09-27 |
ZA200404173B (en) | 2005-08-23 |
KR20050044606A (ko) | 2005-05-12 |
AU2002356927A1 (en) | 2003-06-17 |
HUP0402486A2 (hu) | 2005-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0214437A (pt) | Composto, composição farmacêutica, métodos de modular um receptor ativado por proliferador de peroxissoma, de tratar e de prevenir a diabete melito, e de tratar a sìndrome x, e doenças cardiovasculares em um mamìfero, e, uso de um composto | |
CN101945853B (zh) | 选择性雄激素受体调节剂(sarm)及其应用 | |
BR0009864A (pt) | Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto | |
NZ504191A (en) | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives and their use for treating ocular hypertension | |
BRPI0417687A (pt) | derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade | |
EA200300528A1 (ru) | 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6 | |
AR045173A1 (es) | Compuestos que poseen actividad inhibitoria contra transportador de glucosa dependiente de sodio | |
DE60110262D1 (de) | Thiazol und oxazol-derivate als aktivatoren von menschlichen peroxisom proliferator aktivierten rezeptoren | |
ATE539743T1 (de) | Verfahren zur prävention und behandlung von ppar- vermittelten zuständen mit macelignan | |
BR9812095A (pt) | Compostos de indol como inibidores de cox-2 | |
ATE431345T1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
BRPI0510623A (pt) | compostos de derivados de prolina e morfolina | |
MY154836A (en) | Activating agent for peroxisome prolifrator activated receptor ? | |
TW200700069A (en) | Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives | |
ATE484502T1 (de) | Neue verbindungen | |
TW200740827A (en) | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | |
TW200716547A (en) | Piperidin-4-yl-amide derivatives | |
EA200300716A1 (ru) | Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6 | |
MA31742B1 (fr) | Derives de l'indol-2-one disubstitues en 3, leur preparation et leur application en therapeutique | |
IT1250049B (it) | Composti triciclici. | |
DE602005018672D1 (de) | Konjugate mit entzündungshemmender aktivität | |
UY28377A1 (es) | Agentes terapeuticos | |
AR025103A1 (es) | Quelantes quimicos para la reversion del bloqueo neuromuscular inducido por farmacos | |
ATE455761T1 (de) | Neue atorvastatinsalze und pharmazeutische zusammensetzungen, die diese enthalten | |
MA30540B1 (fr) | Derives de quinolines et compositions pharmaceutiques de ces derives. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A,6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009. |